Monograph: |
Mucopolysaccharide polysulphate (MPS) has been used in medicine as an anti-inflammatory and antithrombotic agent for over 50?years. Its chemical structure permits considerable hydrogen bonding with adjacent water molecules, which effectively leads to hydration of the surrounding tissue. In addition, it stimulates endogenous hyaluronate synthesis, resulting in an increase in water-binding capacity and viscoelasticity of the skin. Mucopolysaccharide polysulphate is a topical (applied to the skin) non-steroidal anti-inflammatory drug (NSAID).
Mucopolysaccharide polysulfate (MPS) is a semi-synthetic
glycosaminoglycan with a mean molecular mass of
9700 with multifold actions. MPS has various effects on
blood coagulation, fibrinolysis and platelet function.
Recently it has been shown in primates that MPS containing
cream increases the release of tissue factor
pathway inhibitor (TFPI) after topical application.
Furthermore, MPS has proven to exert anti-inflammatory
effects and metabolically interacts with the connective
tissue. Animal studies and pharmacological investigations
in humans have shown that, after topical
administration of the MPS, subcutaneous haematomata
and infiltrates are absorbed faster and superficial
thrombi are dissolved more rapidly when compared to
placebo or non-active treatment. In addition, an antiphlogistic
effect was demonstrated in various experimental
inflammation models.
MPS containing cream has been used since several
decades for the topical treatment of superficial thrombophlebitis,
haematomata, and sports injuries. Although
the first clinical experiences with MPS were empirical
the objective evidence of the beneficial effects of such
treatment has later been demonstrated in well designed
placebo controlled double-blind trials. These studies have
shown that per-cutaneous administration of MPS cream
leads to significantly faster regression of acute superficial
thrombophlebitis and of haematomas as well as
significant promotion of the healing of inflammatory
lesions in comparison to placebo.
Β· Movelat contains active anti-inflammatory ingredient mucopolysaccharide polysulphate (MPS) and transcutaneous absorption enhancer salicylic acid
- Salicylic acid breaks down the keratin in the skin, to increase the absorption of MPS3
- Topical administration of MPS increases production of TFPI (Tissue Factor Pathway Inhibitor) to inhibit thrombin formation and reduce inflammation3
Β· Following tissue injury, activation of the arachidonic acid pathway generates two important inflammatory mediators - prostaglandins and leukotrienes1
Β· This leads to the classic symptoms of inflammation such as pain and swelling
MPS blocks the production of a chemical called prostaglandin which the body produces in response to injury or certain diseases. Prostaglandins are responsible for causing swelling, pain and inflammation, and therefore MPS reduces these effects. It is also able to dissolve blood clots and improve the blood supply to the skin. Salicylic acid is included in this preparation to soften
|